Startup Aims to Revolutionize Drug Discovery

By Nicole Hemsoth

May 18, 2007

The advancement of genomics and proteomics via high performance computing is drawing new companies into the drug discovery business. One such company, Gencom Inc., claims its goal is to revolutionize in-silico drug discovery by dramatically speeding up the identification of novel therapeutics. Without external funding, the company has developed a drug discovery platform based on the Intel Itanium 2 hardware. At April's Intel Developer's Forum, Gencom received an Honorable Mention in the Itanium Solutions Alliance's Humanitarian Impact awards for its use of Itanium to advance functional genomics.

Recently, we got the opportunity to ask Gencom's founder and chief technology architect, Michael J. Colonna, about the company and the nature of the technology it has developed.

HPCwire: Could you give us a brief overview of Gencom's history, your vision as the founder, and where the company stands today as far as products and services offered?

Colonna: Gencom was founded in 2002 with an initial vision that was focused on improving computational performance in the area of molecular modeling with the ultimate goal of improving drug-to-market times. At the time, many of the most simplistic models were taking up to 30 days to process on some of the most powerful computers available. It was obvious that bigger and faster servers with increasingly more processors were not getting the job done. 

We decided to take an entirely different approach towards the analysis of the problem which started with a decomposition of the entire process, beginning with the models themselves. The decomposition of the models revealed significant deficiencies in terms of how the models were constructed. This served to establish our first goal which was to develop platform independent “pre-processing” optimization software that would restructure the models for optimal computational performance. We put together some code and tested a simple model consisting of a single gene-protein pair and the results were very promising.

During the course of our analysis it became evident that even if we improved computational performance of the models, there were other deficiencies, both process and technical, that threatened to trivialize the results of our efforts. This led to a significant expansion of our scope which included a rather lofty goal to optimize the entire drug discovery process. We started the entire analysis over, beginning with a business modeling exercise that revealed numerous process and technical candidates for optimization and established the high-level requirements for our technical architecture.

Today, Gencom offers its clientele a full suite of complimentary services that are designed exclusively to improve their ability to more rapidly identify new drug candidates, provide early identification of high-risk candidates and expedite the discovery-to-market process in order to bring more drugs to market, faster, more efficiently and more safely. The services include fully validated on-demand high performance computing, in-silico forced degradation modeling and discovery-focused electronic data capture.

HPCwire: Can you discuss the GENeSYS technology: its unique attributes, the nature of the hardware and software, its performance attributes, and what kinds of users and applications it's targeted for?

Colonna: GENeSYS [pronounced Genesis] is our second generation computing architecture that began its life as Black Widow. Like Black Widow, GENeSYS consists of seven software components that work together to address each of the optimization requirements and the Unifying Platform which, among other things, brings together and normalizes various genomic and proteomic data from the public domain. GENeSYS includes all of the optimization components of Black Widow but is significantly improved in terms of its ability to narrow the focus of drug candidates through constraint-based simulations of metabolic networks and contains improvements in the ability to predict chemical and biological degradation.

The first challenge required us to rethink the computational requirements that would be necessary to achieve our goals. This led to the development of a technical architecture that would run the optimization software components which included the need to dynamically allocate system resources as required based on the complexity of the models. We called the approach “hyper-mesh” or G2 — grid computing on steroids — due to its ability to scale dynamically, create multiple virtual processors and encapsulate and isolate multiple processes to eliminate the risk of process “bleed-over.”

The architecture at this point was technology independent in that we had only defined the requirements without consideration for deployment. It was essentially an exercise that permitted us to dream big and scale back if necessary, based upon limitations of available hardware. Given our initial load projections, we knew that it would be a tall order for any processor to fill and we even considered various contingencies that would get us close to where we wanted to be. One of the many tracks of the analysis and design phase included an assessment of available hardware architectures that could conceivably deliver the type of performance we were hoping for. 

Enter EPIC, Itanium's Explicitly Parallel Instruction Computing architecture. As a purely intellectual exercise, we overlaid EPIC and competing architectures with models of biological systems in an attempt to identify analogs that would ultimately support the software architecture which was modeled on functional biology. Much to our surprise, this turned out to be a fairly good indicator as to the likelihood that the processor architecture would be suitable for our purposes.

The second iteration of analysis and design was focused on a proof of concept for the Itanium and EPIC. Based upon our rough calculations, we could conceivably reduce turnaround time to somewhere in the millisecond range as opposed to weeks. Being absolutely cynical and convinced that our calculations were flawed, we solicited objective validation from various independent subject matter experts and they all confirmed that “on paper”, our assumptions and calculations appeared to be accurate.

This was sufficient for us to commit to the development of an initial prototype. Black Widow Lite was cobbled together using bailing wire and duct tape, figuratively speaking, and contained limited-utility versions of the seven software components written in C++, each strung loosely together with PERL. It was so fragile that we often joked that everyone had to hold their breath during testing for fear that it would completely unravel with the slightest movement. It was not very pretty but it served to validate our initial assumptions and calculations.

The current iteration of GENeSYS is written in C# and PERL has been replaced with F# due to its scripting capabilities which are far more efficient and elegant in execution. Using our own measure of computational speed, we have been able to derive the equivalent of 700 teraflops in terms of overall throughput. While our measure of speed would not stand in terms of the requirements to make the Top 500 list, we are more concerned with measuring overall performance based upon computation of multi-dimensional biological organisms which is a bit different than measuring purely clock speed, I/O, etc. Ultimately, we are not interested in making the list, rather we are interested in identifying drug candidates.

Early in the inception stage, we leaned towards the use of Microsoft-based technologies due to our collective experiences using other technologies and vendors in the past, which were less than positive. As a startup, we were confident that Microsoft would provide us with a level of support, that with limited resources, other vendors simply would not. That added an additional challenge as most of the development on Itanium was on Linux-based machines so we knew that there would be very little history to draw upon in terms of lesson learned. In hindsight, we are confident that we made the right decision for numerous reasons.

In terms of applicability, the utility of GENeSYS is extremely broad and could be applied in many areas where large-scale computational modeling is required. While we had numerous discussions in terms of the breadth of applicability, we made a strategic decision to focus exclusively on drug discovery optimization and the unique requirements associated with FDA compliance to eliminate any further complexity. 

HPCwire: What is the rationale behind the use of an Itanium-based platform, as opposed to say an x86-based cluster or a capability type supercomputer, such an IBM Blue Gene or a Cray system?

Colonna: We had always envisioned a multi-threaded approach to software optimization, possibly on HT equipped x86-based servers, but found that EPIC provided far more capability in terms of overall throughput than we could achieve with 10 times the number of x86 machines, and this was prior to the release of the dual-core Montecito. Blue Gene or any of the other supercomputers of that type would most likely have limited our creativity in terms of development and also deployment.

The days of supercomputers, I believe, are long gone and we are now in the age of “superclusters” and the Itanium is the “big gun” on the block in terms of large-scale computational modeling capabilities. Now, with the dual-core Itanium which significantly reduces power consumption while improving overall performance, the field of in-silico drug discovery could be changed forever. Our hope is that Big Pharma and biotech organizations will apply some of their brainpower and brawn towards the development of applications that could significantly improve the quality of life for all of us. That should be the goal of any technology.

HPCwire: Are there users today, beta or otherwise, that you can talk about?

Colonna: We partnered early on with five biotech companies (NDA's prevent disclosure of their names) that would act as pilots during the development process and help with the definition of requirements. That number has now increased to seven; and as part of our initial agreement and in return for their invaluable guidance, they have an exclusive right to use the technology for a prescribed period of time. GENeSYS is currently going through validation. The inclusion of the metabolic signaling pathway functionality has proven to be far more complex than with Black Widow. So far, we are absolutely thrilled with what has been accomplished and are awaiting approval of the first drug discovered on GENeSYS with hopefully many more to come.

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

At SC19: What Is UrgentHPC and Why Is It Needed?

November 14, 2019

The UrgentHPC workshop, taking place Sunday (Nov. 17) at SC19, is focused on using HPC and real-time data for urgent decision making in response to disasters such as wildfires, flooding, health emergencies, and accidents. We chat with organizer Nick Brown, research fellow at EPCC, University of Edinburgh, to learn more. Read more…

By Tiffany Trader

China’s Tencent Server Design Will Use AMD Rome

November 13, 2019

Tencent, the Chinese cloud giant, said it would use AMD’s newest Epyc processor in its internally-designed server. The design win adds further momentum to AMD’s bid to erode rival Intel Corp.’s dominance of the glo Read more…

By George Leopold

NCSA Industry Conference Recap – Part 1

November 13, 2019

Industry Program Director Brendan McGinty welcomed guests to the annual National Center for Supercomputing Applications (NCSA) Industry Conference, October 8-10, on the University of Illinois campus in Urbana (UIUC). One hundred seventy from 40 organizations attended the invitation-only, two-day event. Read more…

By Elizabeth Leake, STEM-Trek

Cray, Fujitsu Both Bringing Fujitsu A64FX-based Supercomputers to Market in 2020

November 12, 2019

The number of top-tier HPC systems makers has shrunk due to a steady march of M&A activity, but there is increased diversity and choice of processing components with Intel Xeon, AMD Epyc, IBM Power, and Arm server ch Read more…

By Tiffany Trader

Intel AI Summit: New ‘Keem Bay’ Edge VPU, AI Product Roadmap

November 12, 2019

At its AI Summit today in San Francisco, Intel touted a raft of AI training and inference hardware for deployments ranging from cloud to edge and designed to support organizations at various points of their AI journeys. The company revealed its Movidius Myriad Vision Processing Unit (VPU)... Read more…

By Doug Black

AWS Solution Channel

Making High Performance Computing Affordable and Accessible for Small and Medium Businesses with HPC on AWS

High performance computing (HPC) brings a powerful set of tools to a broad range of industries, helping to drive innovation and boost revenue in finance, genomics, oil and gas extraction, and other fields. Read more…

IBM Accelerated Insights

Help HPC Work Smarter and Accelerate Time to Insight

 

[Attend the IBM LSF & HPC User Group Meeting at SC19 in Denver on November 19]

To recklessly misquote Jane Austen, it is a truth, universally acknowledged, that a company in possession of a highly complex problem must be in want of a massive technical computing cluster. Read more…

SIA Recognizes Robert Dennard with 2019 Noyce Award

November 12, 2019

If you don’t know what Dennard Scaling is, the chances are strong you don’t labor in electronics. Robert Dennard, longtime IBM researcher, inventor of the DRAM and the fellow for whom Dennard Scaling was named, is th Read more…

By John Russell

Cray, Fujitsu Both Bringing Fujitsu A64FX-based Supercomputers to Market in 2020

November 12, 2019

The number of top-tier HPC systems makers has shrunk due to a steady march of M&A activity, but there is increased diversity and choice of processing compon Read more…

By Tiffany Trader

Intel AI Summit: New ‘Keem Bay’ Edge VPU, AI Product Roadmap

November 12, 2019

At its AI Summit today in San Francisco, Intel touted a raft of AI training and inference hardware for deployments ranging from cloud to edge and designed to support organizations at various points of their AI journeys. The company revealed its Movidius Myriad Vision Processing Unit (VPU)... Read more…

By Doug Black

IBM Adds Support for Ion Trap Quantum Technology to Qiskit

November 11, 2019

After years of percolating in the shadow of quantum computing research based on superconducting semiconductors – think IBM, Rigetti, Google, and D-Wave (quant Read more…

By John Russell

Tackling HPC’s Memory and I/O Bottlenecks with On-Node, Non-Volatile RAM

November 8, 2019

On-node, non-volatile memory (NVRAM) is a game-changing technology that can remove many I/O and memory bottlenecks and provide a key enabler for exascale. That’s the conclusion drawn by the scientists and researchers of Europe’s NEXTGenIO project, an initiative funded by the European Commission’s Horizon 2020 program to explore this new... Read more…

By Jan Rowell

MLPerf Releases First Inference Benchmark Results; Nvidia Touts its Showing

November 6, 2019

MLPerf.org, the young AI-benchmarking consortium, today issued the first round of results for its inference test suite. Among organizations with submissions wer Read more…

By John Russell

Azure Cloud First with AMD Epyc Rome Processors

November 6, 2019

At Ignite 2019 this week, Microsoft's Azure cloud team and AMD announced an expansion of their partnership that began in 2017 when Azure debuted Epyc-backed instances for storage workloads. The fourth-generation Azure D-series and E-series virtual machines previewed at the Rome launch in August are now generally available. Read more…

By Tiffany Trader

Nvidia Launches Credit Card-Sized 21 TOPS Jetson System for Edge Devices

November 6, 2019

Nvidia has launched a new addition to its Jetson product line: a credit card-sized (70x45mm) form factor delivering up to 21 trillion operations/second (TOPS) o Read more…

By Doug Black

In Memoriam: Steve Tuecke, Globus Co-founder

November 4, 2019

HPCwire is deeply saddened to report that Steve Tuecke, longtime scientist at Argonne National Lab and University of Chicago, has passed away at age 52. Tuecke Read more…

By Tiffany Trader

Supercomputer-Powered AI Tackles a Key Fusion Energy Challenge

August 7, 2019

Fusion energy is the Holy Grail of the energy world: low-radioactivity, low-waste, zero-carbon, high-output nuclear power that can run on hydrogen or lithium. T Read more…

By Oliver Peckham

Using AI to Solve One of the Most Prevailing Problems in CFD

October 17, 2019

How can artificial intelligence (AI) and high-performance computing (HPC) solve mesh generation, one of the most commonly referenced problems in computational engineering? A new study has set out to answer this question and create an industry-first AI-mesh application... Read more…

By James Sharpe

Cray Wins NNSA-Livermore ‘El Capitan’ Exascale Contract

August 13, 2019

Cray has won the bid to build the first exascale supercomputer for the National Nuclear Security Administration (NNSA) and Lawrence Livermore National Laborator Read more…

By Tiffany Trader

DARPA Looks to Propel Parallelism

September 4, 2019

As Moore’s law runs out of steam, new programming approaches are being pursued with the goal of greater hardware performance with less coding. The Defense Advanced Projects Research Agency is launching a new programming effort aimed at leveraging the benefits of massive distributed parallelism with less sweat. Read more…

By George Leopold

AMD Launches Epyc Rome, First 7nm CPU

August 8, 2019

From a gala event at the Palace of Fine Arts in San Francisco yesterday (Aug. 7), AMD launched its second-generation Epyc Rome x86 chips, based on its 7nm proce Read more…

By Tiffany Trader

D-Wave’s Path to 5000 Qubits; Google’s Quantum Supremacy Claim

September 24, 2019

On the heels of IBM’s quantum news last week come two more quantum items. D-Wave Systems today announced the name of its forthcoming 5000-qubit system, Advantage (yes the name choice isn’t serendipity), at its user conference being held this week in Newport, RI. Read more…

By John Russell

Ayar Labs to Demo Photonics Chiplet in FPGA Package at Hot Chips

August 19, 2019

Silicon startup Ayar Labs continues to gain momentum with its DARPA-backed optical chiplet technology that puts advanced electronics and optics on the same chip Read more…

By Tiffany Trader

Crystal Ball Gazing: IBM’s Vision for the Future of Computing

October 14, 2019

Dario Gil, IBM’s relatively new director of research, painted a intriguing portrait of the future of computing along with a rough idea of how IBM thinks we’ Read more…

By John Russell

Leading Solution Providers

ISC 2019 Virtual Booth Video Tour

CRAY
CRAY
DDN
DDN
DELL EMC
DELL EMC
GOOGLE
GOOGLE
ONE STOP SYSTEMS
ONE STOP SYSTEMS
PANASAS
PANASAS
VERNE GLOBAL
VERNE GLOBAL

Intel Confirms Retreat on Omni-Path

August 1, 2019

Intel Corp.’s plans to make a big splash in the network fabric market for linking HPC and other workloads has apparently belly-flopped. The chipmaker confirmed to us the outlines of an earlier report by the website CRN that it has jettisoned plans for a second-generation version of its Omni-Path interconnect... Read more…

By Staff report

Kubernetes, Containers and HPC

September 19, 2019

Software containers and Kubernetes are important tools for building, deploying, running and managing modern enterprise applications at scale and delivering enterprise software faster and more reliably to the end user — while using resources more efficiently and reducing costs. Read more…

By Daniel Gruber, Burak Yenier and Wolfgang Gentzsch, UberCloud

Dell Ramps Up HPC Testing of AMD Rome Processors

October 21, 2019

Dell Technologies is wading deeper into the AMD-based systems market with a growing evaluation program for the latest Epyc (Rome) microprocessors from AMD. In a Read more…

By John Russell

Rise of NIH’s Biowulf Mirrors the Rise of Computational Biology

July 29, 2019

The story of NIH’s supercomputer Biowulf is fascinating, important, and in many ways representative of the transformation of life sciences and biomedical res Read more…

By John Russell

Xilinx vs. Intel: FPGA Market Leaders Launch Server Accelerator Cards

August 6, 2019

The two FPGA market leaders, Intel and Xilinx, both announced new accelerator cards this week designed to handle specialized, compute-intensive workloads and un Read more…

By Doug Black

When Dense Matrix Representations Beat Sparse

September 9, 2019

In our world filled with unintended consequences, it turns out that saving memory space to help deal with GPU limitations, knowing it introduces performance pen Read more…

By James Reinders

With the Help of HPC, Astronomers Prepare to Deflect a Real Asteroid

September 26, 2019

For years, NASA has been running simulations of asteroid impacts to understand the risks (and likelihoods) of asteroids colliding with Earth. Now, NASA and the European Space Agency (ESA) are preparing for the next, crucial step in planetary defense against asteroid impacts: physically deflecting a real asteroid. Read more…

By Oliver Peckham

Cerebras to Supply DOE with Wafer-Scale AI Supercomputing Technology

September 17, 2019

Cerebras Systems, which debuted its wafer-scale AI silicon at Hot Chips last month, has entered into a multi-year partnership with Argonne National Laboratory and Lawrence Livermore National Laboratory as part of a larger collaboration with the U.S. Department of Energy... Read more…

By Tiffany Trader

  • arrow
  • Click Here for More Headlines
  • arrow
Do NOT follow this link or you will be banned from the site!
Share This